Insights into monkeypox pathophysiology, global prevalence, clinical manifestation and treatments
L Niu, D Liang, Q Ling, J Zhang, Z Li, D Zhang… - Frontiers in …, 2023 - frontiersin.org
On 23rd July 2022, the World Health Organization (WHO) recognized the ongoing
monkeypox outbreak as a public medical crisis. Monkeypox virus (MPV), the etiological …
monkeypox outbreak as a public medical crisis. Monkeypox virus (MPV), the etiological …
A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir/ritonavir
J Gerhart, DS Cox, RSP Singh, PLS Chan… - Clinical …, 2024 - Springer
Nirmatrelvir is a potent and selective inhibitor of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus …
coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus …
Proof-of-concept studies with a computationally designed Mpro inhibitor as a synergistic combination regimen alternative to Paxlovid
As the SARS-CoV-2 virus continues to spread and mutate, it remains important to focus not
only on preventing spread through vaccination but also on treating infection with direct …
only on preventing spread through vaccination but also on treating infection with direct …
Curcumin for the treatment of COVID‐19 patients: a meta‐analysis of randomized controlled trials
Curcumin is a low‐cost and easily accessible therapeutic option for COVID‐19 patients. We
aimed to conduct a meta‐analysis to assess the effect of curcumin on clinical outcomes in …
aimed to conduct a meta‐analysis to assess the effect of curcumin on clinical outcomes in …
Synthetic approaches to the new drugs approved during 2021
EL McInturff, SP France, CA Leverett… - Journal of Medicinal …, 2023 - ACS Publications
Each year, new drugs are introduced to the market, representing structures that have affinity
for biological targets implicated in human diseases and conditions. These new chemical …
for biological targets implicated in human diseases and conditions. These new chemical …
Structure-based design of SARS-CoV-2 papain-like protease inhibitors
The COVID-19 pandemic is caused by SARS-CoV-2, an RNA virus with high transmissibility
and mutation rate. Given the paucity of orally bioavailable antiviral drugs to combat SARS …
and mutation rate. Given the paucity of orally bioavailable antiviral drugs to combat SARS …
Clinical outcomes following treatment for COVID-19 with nirmatrelvir/ritonavir and molnupiravir among patients living in nursing homes
BHM Ma, TCF Yip, GCY Lui, MSM Lai, E Hui… - JAMA Network …, 2023 - jamanetwork.com
Importance Older patients living in nursing homes are at very high risk of mortality after
getting COVID-19. Objective To evaluate outcomes following oral antiviral treatment for …
getting COVID-19. Objective To evaluate outcomes following oral antiviral treatment for …
Real-world evidence of the top 100 prescribed drugs in the USA and their potential for drug interactions with nirmatrelvir; ritonavir
J Gerhart, F Draica, M Benigno, J Atkinson… - The AAPS Journal, 2023 - Springer
Nirmatrelvir (coadministered with ritonavir as PAXLOVIDTM) reduces the risk of COVID-19-
related hospitalizations and all-cause death in individuals with mild-to-moderate COVID-19 …
related hospitalizations and all-cause death in individuals with mild-to-moderate COVID-19 …
Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants
DS Cox, M Rehman, T Khan, K Ginman… - British Journal of …, 2023 - Wiley Online Library
Aims To evaluate pharmacokinetics (PK) and safety after coadministration of
nirmatrelvir/ritonavir or ritonavir alone with midazolam (a cytochrome P450 3A4 substrate) …
nirmatrelvir/ritonavir or ritonavir alone with midazolam (a cytochrome P450 3A4 substrate) …
Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
D Yan, B Yan - Fundamental & Clinical Pharmacology, 2023 - Wiley Online Library
The COVID‐19 pandemic remains a major health concern worldwide, and SARS‐CoV‐2 is
continuously evolving. There is an urgent need to identify new antiviral drugs and develop …
continuously evolving. There is an urgent need to identify new antiviral drugs and develop …